| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/16/2011 | WO2011069918A1 Novel medical use |
| 06/16/2011 | WO2011069916A1 Triazole compounds, use thereof as a fungicide, and agents comprising same |
| 06/16/2011 | WO2011069912A1 Triazole compounds, use thereof and agents containing said compounds |
| 06/16/2011 | WO2011069871A1 A method for providing emergency contraception using ulipristal acetate |
| 06/16/2011 | WO2011069761A1 Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof |
| 06/16/2011 | WO2011069688A1 Novel phosph(on)ate- and sulf(on)ate-based phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents |
| 06/16/2011 | WO2011069654A1 Carnitine granulate and methods for its production |
| 06/16/2011 | WO2011069647A1 New 2-aminothiadiazole derivatives |
| 06/16/2011 | WO2011069608A1 S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide |
| 06/16/2011 | WO2011069527A1 Treatment scheme for idd and other automimmune diseases |
| 06/16/2011 | WO2011069487A2 Dna aptamers that specifically bind to the soluble interleukin-6 receptor |
| 06/16/2011 | WO2011069486A1 Rna aptamers that specifically bind to the soluble interleukin-6 receptor |
| 06/16/2011 | WO2011069336A1 Use of saturated amines compounds in manufacture of medicaments for mobilizing peripheral blood hematopoietic stem cell |
| 06/16/2011 | WO2011069335A1 Use of pyridines compounds in preparing rna interference reinforcing agent |
| 06/16/2011 | WO2011069334A1 Cdk5 inhibitors and therapeutic uses thereof |
| 06/16/2011 | WO2011069326A1 Bilayer tablet comprising atenolol and amlodipine |
| 06/16/2011 | WO2011069322A1 Acyclic nucleoside phosphonate derivative and medicine use thereof |
| 06/16/2011 | WO2011069298A1 Novel cyclopropane indolinone derivatives |
| 06/16/2011 | WO2011069294A1 N6-substituted adenosine derivatives, n6-substituted adenine derivatives and uses thereof |
| 06/16/2011 | WO2011069197A1 Inhalable formulations |
| 06/16/2011 | WO2011051967A3 Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof |
| 06/16/2011 | WO2011050211A3 Methods and compositions for cell-proliferation-related disorders |
| 06/16/2011 | WO2011049948A3 Neuroprotection and myelin repair using nestorone® |
| 06/16/2011 | WO2011049629A3 Methods of making and using compositions comprising flavonoids |
| 06/16/2011 | WO2011048564A3 Orally disintegrating tablets of flurbiprofen |
| 06/16/2011 | WO2011047770A3 Pyrazolopyrimidine derivatives |
| 06/16/2011 | WO2011045774A3 Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof |
| 06/16/2011 | WO2011045769A3 Anti-misuse solid oral dosage form provided having a modified specific release profile |
| 06/16/2011 | WO2011045703A3 C-linked hydroxamic acid derivatives useful as antibacterial agents |
| 06/16/2011 | WO2011045068A3 Pharmaceutical composition containing cannabinoid-receptor 2 antagonists |
| 06/16/2011 | WO2011044501A3 Antibacterial aminoglycoside analogs |
| 06/16/2011 | WO2011042872A4 Use of a dna replication inhibitor for treating neurodegenerative diseases caused by polyglutamine expansion |
| 06/16/2011 | WO2011041731A3 Method of inhibiting bcl-2-related survival proteins |
| 06/16/2011 | WO2011039735A3 Compounds with ddx3 inhibitory activity and uses thereof |
| 06/16/2011 | WO2011039554A3 2,3,4-benzothiadiazepine-2,2-dioxide derivatives |
| 06/16/2011 | WO2011039221A3 Phosphoramidate derivatives of nucleosides |
| 06/16/2011 | WO2011031474A3 Use of metformin in cancer treatment and prevention |
| 06/16/2011 | WO2011029547A8 Isoxazolidine derivatives |
| 06/16/2011 | WO2011025167A3 Pharmaceutical composition for preventing or treating cancer comprising 2,6-substituted 3-nitropyridine derivative compound or pharmaceutically acceptable salt thereof |
| 06/16/2011 | WO2011025128A4 Method for treating th17 inflammatory disease through inhibition of vascular endothelial growth factor receptors and pharmaceutical composition therefor |
| 06/16/2011 | WO2011023824A3 Estrogen receptor modulators for the treatment of diseases involving plasmacytoid dendritic cells |
| 06/16/2011 | WO2011022838A8 Polyhydroxylated bile acids for treatment of biliary disorders |
| 06/16/2011 | WO2011022694A3 Furanopyrimidine cannabinoid compounds and related methods of use |
| 06/16/2011 | WO2011022692A3 Furanopyridine cannabinoid compounds and related methods of use |
| 06/16/2011 | WO2011022679A3 Benzofuran cannabinoid compounds and related methods of use |
| 06/16/2011 | WO2011022509A3 Substituted benzoazepines as toll-like receptor modulators |
| 06/16/2011 | WO2011022489A3 (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| 06/16/2011 | WO2011021726A3 Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation |
| 06/16/2011 | WO2011020061A3 Compositions and methods of for treating bipolar disorder |
| 06/16/2011 | WO2011019940A3 Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method for use |
| 06/16/2011 | WO2011019821A3 METHOD FOR MAKING 3α-HYDROXY, 3β- METHYL-5α-PREGNAN-20-ONE (GANAXOLONE) |
| 06/16/2011 | WO2011019393A3 Class- and isoform-specific hdac inhibitors and uses thereof |
| 06/16/2011 | WO2011017600A3 Compositions and methods for treating beta-amyloid related diseases |
| 06/16/2011 | WO2011017346A3 Fast-acting naproxen composition with reduced gastrointestinal effects |
| 06/16/2011 | WO2011017201A3 Dp2 antagonist and uses thereof |
| 06/16/2011 | WO2011017162A9 Methods for enhancing antigen-specific immune responses |
| 06/16/2011 | WO2011017096A3 Methods of treating hematologic cancers |
| 06/16/2011 | WO2011014825A3 Antiangiogenic small molecules and methods of use |
| 06/16/2011 | WO2011014587A3 Ophthalmic pharmaceutical compositions of dp2 receptor antagonists |
| 06/16/2011 | WO2011014475A3 Treating negative symptoms of schizophrenia associated with defective neuregulin 1 |
| 06/16/2011 | WO2011012990A3 Improved pharmacokinetics of s-adenosylmethionine formulations |
| 06/16/2011 | WO2011011733A3 Factor replacement therapy |
| 06/16/2011 | WO2011011420A3 3, 4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor |
| 06/16/2011 | WO2011009039A3 Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
| 06/16/2011 | WO2011008298A3 Novel axomadol dosage forms |
| 06/16/2011 | WO2010149794A3 Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane) |
| 06/16/2011 | WO2010136105A3 Ammoniumcarboxylates |
| 06/16/2011 | WO2010122490A3 A medicinal anti diaper rash cream incorporating a biopolymer and a process to make it |
| 06/16/2011 | WO2010121576A3 Novel 7-deazapurine nucleosides for therapeutic uses |
| 06/16/2011 | WO2010117860A3 Microrna signature to predict prognosis in heart failure |
| 06/16/2011 | WO2010100476A3 Improved process |
| 06/16/2011 | WO2010097243A3 Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts |
| 06/16/2011 | WO2010096886A3 Composition of a liposomal gel containing hydrocortisone, its metabolites, precursors or mixtures thereof and the use thereof |
| 06/16/2011 | WO2010085609A3 Controlled release systems from polymer blends |
| 06/16/2011 | WO2010075065A3 Methods for enhancing the release and absorption of water insoluble active agents |
| 06/16/2011 | US20110144577 Hydrophilic coatings with tunable composition for drug coated balloon |
| 06/16/2011 | US20110144338 Methods of reducing risk of infection from pathogens |
| 06/16/2011 | US20110144330 2,4-Pyrimidinediamine Compounds and their Uses |
| 06/16/2011 | US20110144320 N-pyrazole a2a receptor agonists |
| 06/16/2011 | US20110144316 Method for restructuring the epidermis using a polyol-glycoside composition |
| 06/16/2011 | US20110144309 Manipulation of Cytokine Levels Using CD83 Gene Products |
| 06/16/2011 | US20110144215 Bruise amelioration composition and method of use |
| 06/16/2011 | US20110144214 Hydroalcoholic gel compositions for use with dispensers |
| 06/16/2011 | US20110144213 Anhydrous depigmenting compositions comprising a solubilized phenolic compound |
| 06/16/2011 | US20110144212 Key intermediate for the preparation of stilbenes, solid forms of pterostilbene, and methods for making the same |
| 06/16/2011 | US20110144211 Use of microcrystalline cellulose for interfering with the extraction of ephedrine |
| 06/16/2011 | US20110144210 Stable dosage forms of levomilnacipran |
| 06/16/2011 | US20110144209 Use of vasoconstrictors |
| 06/16/2011 | US20110144208 Cosmetic compositions comprising at least one bis-urea derivative |
| 06/16/2011 | US20110144207 Aryl alkyl carboxylic acid salts, process for preparation and dosage forms |
| 06/16/2011 | US20110144206 Use of a cox-2 inhibitor for the treatment of a cox-2 dependent disorder in a patient not carrying hla alleles associated with hepatotoxicity |
| 06/16/2011 | US20110144205 Blood Glutathione as a Biomarker for Screening Asymptomatic Patients at Risk for Heart Failure |
| 06/16/2011 | US20110144204 Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
| 06/16/2011 | US20110144202 Concentrated oxaliplatin solution and its method of preparation |
| 06/16/2011 | US20110144201 Method for improving the tolerance of crops to chilling temperatures and/or frost |
| 06/16/2011 | US20110144200 Combination of carotenoids and epi-lutein |
| 06/16/2011 | US20110144199 Methods for treating atrial fibrillation |
| 06/16/2011 | US20110144198 Breast cancer prognostics |
| 06/16/2011 | US20110144197 Alcanoic acid amides substituted by saturated o-heterocycles |
| 06/16/2011 | US20110144196 Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof |